Mark Waer
About
In The Last Decade
Mark Waer
240 papers receiving 5.7k citations
Hit Papers
Peers
Comparison fields: 5 of 116
- Immunology 2.4k
- Pathology and Forensic Medicine 1.4k
- Surgery 1.3k
- Genetics 1.1k
- Reproductive Medicine 912
Countries citing papers authored by Mark Waer
This map shows the geographic impact of Mark Waer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Waer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Waer more than expected).
Fields of papers citing papers by Mark Waer
This network shows the impact of papers produced by Mark Waer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Waer. The network helps show where Mark Waer may publish in the future.
Co-authorship network of co-authors of Mark Waer
This figure shows the co-authorship network connecting the top 25 collaborators of Mark Waer. A scholar is included among the top collaborators of Mark Waer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Waer. Mark Waer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 4 | |
| 3 | 8 | |
| 4 | The importance of persisting allo-stimulation for the maintenance of tolerance and regulatory T cells | 1 |
| 5 | 32 | |
| 6 | Calcineurin inhibitor immunosuppression: "Less and later is more" | 1 |
| 7 | Translation into the clinic of an experimentally proven pro-regulatory immunomodulatory protocol for intestinal transplantation. Long-term results | 1 |
| 8 | Calcineurin inhibitor: Influence of dose and timing on regulatory cells and graft acceptance | 1 |
| 9 | Role of growth arrest specific gene 6 in immune and non-immune aspects of vascular lesions occurring during delayed xenograft rejection | 4 |
| 10 | 60 | |
| 11 | 33 | |
| 12 | Complete freedom from rejection, infection and drug toxicity after intestinal transplantation using a new tolerogenic protocol combined with low immunosuppression | 1 |
| 13 | Interleukin-1 receptor antagonist inhibits primary non-function and prolongs graft survival time of xenogeneic islets transplanted in spontaneously diabetic autoimmune NOD mice | 4 |
| 14 | Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is involved in the pathogenesis of chronic allograft vasculopathy | 1 |
| 15 | 17 | |
| 16 | Effect of sex hormones on apoptosis in NOD mice: Link to autoimmunity | 1 |
| 17 | Xanthines: ideal immunosuppressants for combination with cyclosporine? | 0 |
| 18 | Phenotypic and functional-analysis of suppressor cells in renal-transplant recipients receiving cyclosporine-a or preoperative total lymphoid irradiation | 1 |
| 19 | A controlled trial of one month versus 3 months cyclosporine and conversion to azathioprine in renal-transplantation | 1 |
| 20 | Are cyclosporine-treated hla-drw6-positive cadaveric kidney allograft recipients high responders | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.